LEIDEN, NETHERLANDS--(Marketwire - July 11, 2008) - OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it will receive an additional EUR 2 million under the terms of its bridge financing, which was announced on 28 March. The payment is made by the Company’s co-development partner in Locteron®, Biolex Therapeutics, Inc. The additional bridge financing will enable OctoPlus to secure one of the longer term financing options currently under negotiation.
